article thumbnail

Scientific workflow for hypothesis testing in drug discovery: Part 1

Drug Target Review

In cases where control or treatment groups show large variability, this could reflect true biological responses to a treatment, and removing such data could reduce the accuracy of the analysis. In 2003, he was selected by EE Times as one of the top 13 most influential people in the semiconductor industry.

RNA 52
article thumbnail

CAR-NK cells: promising for cancer therapy

Drug Target Review

Only three of the CAR-NK studies were for the treatment of solid tumours. By themselves, the NK cells showed limited efficacy, but anti-tumour efficacy was observed with co-treatment regimens (eg, monoclonal antibodies, haematopoietic stem cell transplants, whole body irradiation) and multiple dosing (tolerated well by patients).

Therapies 118
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Approves Klisyri (tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp

The Pharma Data

FDA Approves Klisyri (tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp. NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the U.S. BUFFALO, N.Y.,

article thumbnail

Gamma delta T cells: a rising star in cancer therapy

Drug Target Review

Over the past 25 years, T-cell therapies have gained significant ground in the treatment of cancer. from 2003 to 2006, covering the biotechnology and life-science tools sectors. J Exp Med 198(5):747-755 (2003). Liu Z, Eltoum I-E, Guo B, et al. J Immunol 180(9):6044-6053 (2008). Lamb L, Pereboeva L, Youngblood S, et al.

Therapies 105
article thumbnail

FDA accepts application for self-administered Xolair use

The Pharma Data

It is the only biologic approved which is designed to target and block immunoglobin E (IgE) for the treatment of moderate-to-severe persistent allergic asthma and chronic idiopathic urticaria (CIU). Approximately 460,000 patients in the US have been treated with Xolair since its first approval for allergic asthma back in 2003.

FDA 52
article thumbnail

Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir

The Pharma Data

At a time where there is unmet need for antiviral treatments against SARS-CoV-2, we are encouraged by these preliminary data.”. Molnupiravir has been shown to be active in several models of SARS-CoV-2, including for prophylaxis, treatment, and prevention of transmission, as well as SARS-CoV-1 and MERS.

Trials 69
article thumbnail

Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications

The Pharma Data

Xolair for self-injection offers healthcare providers and appr opriate patients another administration option for more flexibility in managing their treatment. with Xolair since its initial approval in 2003. today announced that the U.S. indications. indications. Roche’s Chief Medical Officer and Head of Global Product Development.